READ: Featured Drug Insights: June 2025 - Prime Therapeutics
READ: Featured Drug Insights: June 2025
Your source for all Prime Therapeutics' June 2025 Drug Insights publications.
Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for June 2025 will keep you informed on what’s trending now and trending clinical topics.
Released July 1, 2025
NEW! Trending Topics & Drug Approvals: June 2025
We've combined Clinical Highlights and Drug Approvals into this new, monthly publication, which covers the latest specialty and traditional drug approvals. The latest edition features recent changes to the CDC's Advisory Committee for Immunization Practices.
Released June 4, 2025
A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are deramiocel, apitegromab, celmidsogene lanparvovec and more.
Released June 18, 2025
Providing a clinical deep dive into a select high-cost drug in the pipeline, this month's profile features AdenoVerse, a gene therapy designed to elicit an immune response against cells infected with human papillomavirus (HPV) 6 or HPV 11.
Released June 18, 2025
FDA Decisions Expected: July 2025
A breakdown of FDA decisions expected of new drugs anticipated to hit the market, this edition covers zongertinib, sunvozertinib, linvoseltamab and more.
Released June 25, 2025
Featuring commentary by Simone Ndujiuba, PharmD, BCOP on developments in the oncology space, this installment highlights innovative antibody drugs called bispecific T-cell engagers (BiTE) to treat a variety of cancers, including both blood and solid tumor cancers.
Looking for previous 2025 drug insights publications?
Simply click on the month to access past editions of our drug insights.
All brand names are property of their respective owners.